EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents

Carlos Gaona-López, Domingo Méndez-Álvarez, Adriana Moreno-Rodríguez iD, Juan Luis Bautista-Martínez iD, José Antonio De Fuentes-Vicente, Benjamín Nogueda-Torres iD, Itzhel García-Torres, Gabriel López-Velázquez iD, Gildardo Rivera iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25116238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Carlos Gaona-López und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico. Hauptthemen laut MEDLINE: Giardiasis, Giardia lamblia, Molecular Docking Simulation, Antiprotozoal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parasitic diseases, predominantly prevalent in developing countries, are increasingly spreading to high-income nations due to shifting migration patterns. The World Health Organization (WHO) estimates approximately 300 million annual cases of giardiasis. The emergence of drug resistance and associated side effects necessitates urgent research to address this growing health concern. In this study, we evaluated over eleven thousand pharmacological compounds sourced from the FDA database to assess their impact on the TATA-binding protein (TBP) of the early diverging protist Giardia lamblia, which holds medical significance. We identified a selection of potential pharmacological compounds for combating this parasitic disease through in silico analysis, employing molecular modeling techniques such as homology modeling, molecular docking, and molecular dynamics simulations. Notably, our findings highlight compounds DB07352 and DB08399 as promising candidates for inhibiting the TBP of Giardia lamblia. Also, these compounds and DB15584 demonstrated high efficacy against trophozoites in vitro. In summary, this study identifies compounds with the potential to combat giardiasis, offering the prospect of specific therapies and providing a robust foundation for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GiardiasisGiardia lambliaMolecular Docking SimulationAntiprotozoal AgentsUnited States Food and Drug AdministrationUnited StatesHumansProtozoan ProteinsMolecular Dynamics Simulation

Stichwörter der Autor:innen

FDAGiardia lambliaTATA-binding proteindrug repositioninginhibitors

Substanzen

Antiprotozoal AgentsProtozoan Proteins

Autor:innen und Institutionen

  • Laboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa 88710, Mexico.
  • Laboratorio de Estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de Ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Oaxaca 68120, Mexico.
  • Instituto de Ciencias Biológicas, Universidad de Ciencias y Artes de Chiapas, Tuxtla Gutiérrez 29039, Mexico.
  • Departamento de Parasitología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  • Laboratorio de Biomoléculas y Salud Infantil, Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico.

ORCID-Profile: Adriana Moreno-Rodríguez, Juan Luis Bautista-Martínez, Benjamín Nogueda-Torres, Gabriel López-Velázquez, Gildardo Rivera

Förderung

  • Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional

Zitieren

APA

Gaona-López, C., Méndez-Álvarez, D., Moreno-Rodríguez, A., Bautista-Martínez, J. L., De Fuentes-Vicente, J. A., Nogueda-Torres, B., García-Torres, I., López-Velázquez, G., & Rivera, G. (2024). TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25116238

Vancouver

Gaona-López C, Méndez-Álvarez D, Moreno-Rodríguez A, Bautista-Martínez JL, De Fuentes-Vicente JA, Nogueda-Torres B, et al. TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25116238

BibTeX
@article{GaonaLpez2024,
  author = {Gaona-López, Carlos and Méndez-Álvarez, Domingo and Moreno-Rodríguez, Adriana and Bautista-Martínez, Juan Luis and De Fuentes-Vicente, José Antonio and Nogueda-Torres, Benjamín and García-Torres, Itzhel and López-Velázquez, Gabriel and Rivera, Gildardo},
  title = {TATA-Binding Protein-Based Virtual Screening of FDA Drugs Identified New Anti-Giardiasis Agents},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25116238}
}
Kostenlos starten →